PMID- 36589672
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 25
IP  - 1
DP  - 2023 Jan
TI  - Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in 
      heavily pretreated and/or fragile patients with PDL1-positive 
      recurrent/metastatic head and neck cancer.
PG  - 37
LID - 10.3892/ol.2022.13623 [doi]
LID - 37
AB  - Novel chemo-immunotherapy (chemo-IO) combinations should be evaluated, which may 
      be suitable for cisplatin-unfit or fluoropyrimide-ineligible patients with 
      recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) to 
      guarantee higher and deeper responses than IO alone. The aim of the present study 
      was to review our experience using pembrolizumab-carboplatin-paclitaxel (pembro + 
      CP) in patients with R/M SCCHN. This was a retrospective study of patients with 
      R/M SCCHN who received pembro + CP in any-line via a compassionate-use program. 
      The present study evaluated safety using Common Terminology Criteria for Adverse 
      Events v4.0, compliance, overall response rate (ORR) and disease control rate 
      (DCR) using Response Evaluation Criteria in Solid Tumors 1.1, duration of 
      treatment, progression-free survival (PFS) and overall survival (OS). Between 
      March 2020 and August 2021, 10 patients were identified (median age, 64 years; 
      female, 60%; Eastern Cooperative Oncology Group 2, 80%). A total of 8 patients 
      received pembro + 3-weekly carboplatin-paclitaxel (3wkCP). A total of 2 patients 
      received pembro + weekly carboplatin-paclitaxel (wkCP). Patients received a 
      median of 3 lines (range, 0-6) of systemic therapy prior to pembro + CP and 80% 
      received IO in previous lines. Grade 1-2 adverse events (AEs) occurred in 100% of 
      patients. Grade 3-5 AEs occurred in 30% of patients [all grade 3 (anemia, 
      neutropenia, thrombopenia, hypertension)]. The mean numbers of pembro + wkCP and 
      pembro + 3wkCP cycles were 2.5 and 6. The ORR (n=7) was 14% (1/7) with one 
      complete response. The DCR was 43% (3/7). The median PFS (n=7) and OS (n=10) 
      times since pembro + CP were 5 months (95% CI, 1-9) and 6 months (95% CI, 
      0.5-14), respectively. In this small retrospective series of heavily pretreated 
      patients, pembro + CP was well tolerated, and compliance was high. Studies should 
      be conducted to prospectively evaluate the safety and efficacy of this 
      combination in patients with R/M SCCHN.
CI  - Copyright: (c) Cabezas-Camarero et al.
FAU - Cabezas-Camarero, Santiago
AU  - Cabezas-Camarero S
AD  - Head and Neck Cancer, Neuro-Oncology and Genetic Counseling Unit, Medical 
      Oncology Department, Instituto de Investigacion Sanitaria San Carlos, Madrid 
      28040, Spain.
FAU - Merino-Menendez, Salome
AU  - Merino-Menendez S
AD  - Radiology Department, Clinico San Carlos University Hospital, Madrid 28040, 
      Spain.
FAU - Cabrera-Martin, Maria Nieves
AU  - Cabrera-Martin MN
AD  - Nuclear Medicine Department, Clinico San Carlos University Hospital, Madrid 
      28040, Spain.
FAU - Sotelo, Miguel J
AU  - Sotelo MJ
AD  - Medical Oncology Department, Aliada Cancer Center, San Isidro 15036, Peru.
AD  - Medical Oncology Department, San Felipe Hospital, Jesus Maria 15072, Peru.
AD  - Medical Oncology Department, Maria Auxiliadora Hospital, San Juan de Miraflores 
      15801, Peru.
FAU - Plaza-Hernandez, Jose Carlos
AU  - Plaza-Hernandez JC
AD  - Pathology Department, Clinico San Carlos University Hospital, Madrid 28040, 
      Spain.
FAU - Falahat, Farzin
AU  - Falahat F
AD  - Department of Craniomaxilofacial Surgery, Clinico San Carlos University Hospital, 
      Madrid 28040, Spain.
FAU - Iglesias-Moreno, Maria Cruz
AU  - Iglesias-Moreno MC
AD  - Department of Otolaryngology-Head and Neck Surgery, Clinico San Carlos University 
      Hospital, Madrid 28040, Spain.
FAU - Perez-Segura, Pedro
AU  - Perez-Segura P
AD  - Head and Neck Cancer, Neuro-Oncology and Genetic Counseling Unit, Medical 
      Oncology Department, Instituto de Investigacion Sanitaria San Carlos, Madrid 
      28040, Spain.
LA  - eng
PT  - Journal Article
DEP - 20221207
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC9773311
OTO - NOTNLM
OT  - anti-programmed cell death protein 1
OT  - carboplatin
OT  - chemoimmunotherapy
OT  - head and neck cancer
OT  - paclitaxel
OT  - pembrolizumab
COIS- SCC has worked as a consultant and as a Speaker's Bureau representative for 
      Bristol-Myers Squibb, Merck and MSD, and has received grant/research support from 
      clinical trials with AstraZeneca, MSD and Merck. PPS has also worked as a 
      consultant and as a Speaker's Bureau representative for Bristol-Myers Squibb, 
      Merck and MSD, and received grant/research support from clinical trials with 
      Bristol-Myers Squibb, AstraZeneca and MSD. The remainder of the authors declare 
      that they have no competing interests.
EDAT- 2023/01/03 06:00
MHDA- 2023/01/03 06:01
PMCR- 2022/12/07
CRDT- 2023/01/02 04:03
PHST- 2022/09/29 00:00 [received]
PHST- 2022/11/02 00:00 [accepted]
PHST- 2023/01/02 04:03 [entrez]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/03 06:01 [medline]
PHST- 2022/12/07 00:00 [pmc-release]
AID - OL-25-01-13623 [pii]
AID - 10.3892/ol.2022.13623 [doi]
PST - epublish
SO  - Oncol Lett. 2022 Dec 7;25(1):37. doi: 10.3892/ol.2022.13623. eCollection 2023 
      Jan.